{"id":"NCT03329092","sponsor":"Pfizer","briefTitle":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","officialTitle":"A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-05","primaryCompletion":"2023-02-23","completion":"2023-02-23","firstPosted":"2017-11-01","resultsPosted":"2024-05-07","lastUpdate":"2024-12-10"},"enrollment":422,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Complicated Intra-abdominal Infection","Hosptial Acquired Pneumonia","Ventilator Associated Pneumonia"],"interventions":[{"type":"DRUG","name":"ATM-AVI","otherNames":[]},{"type":"DRUG","name":"MTZ","otherNames":[]},{"type":"DRUG","name":"MER","otherNames":[]},{"type":"DRUG","name":"COL","otherNames":[]}],"arms":[{"label":"Aztreonam-Avibactam ± Metronidazole","type":"EXPERIMENTAL"},{"label":"Meropenem ± Colistin","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram negative bacteria.","primaryOutcome":{"measure":"Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set","timeFrame":"At TOC visit (Day 28)","effectByArm":[{"arm":"Aztreonam-avibactam ± Metronidazole","deltaMin":68.4,"sd":null},{"arm":"Meropenem± Colistimethate","deltaMin":65.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":157,"countries":["United States","Argentina","Bulgaria","China","Croatia","Czechia","Greece","India","Israel","Italy","Malaysia","Mexico","Philippines","Romania","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["40530972","39389071","38252170"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C3601002"]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":275},"commonTop":["Anaemia","Alanine aminotransferase increased","Diarrhoea","Aspartate aminotransferase increased","Hypokalaemia"]}}